EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tourmaline Bio's enterprise value is $169.34 Mil.
Tourmaline Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-14.57 Mil. Therefore, Tourmaline Bio's EV-to-EBITDA for today is -11.62.
The historical rank and industry rank for Tourmaline Bio's EV-to-EBITDA or its related term are showing as below:
TRML'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -163.58 Med: 0 Max: 38.26
Current: -11.62
During the past 3 years, the highest EV-to-EBITDA of Tourmaline Bio was 38.26. The lowest was -163.58. And the median was 0.00.
TRML's EV-to-EBITDA is ranked worse than 100% of 462
companies
in the Biotechnology industry
Industry Median: 9.49
vs TRML: -11.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Tourmaline Bio EV-to-EBITDA Historical Data
The historical data trend for Tourmaline Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tourmaline Bio's EV-to-EBITDA
For the Biotechnology subindustry, Tourmaline Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tourmaline Bio's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tourmaline Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tourmaline Bio's EV-to-EBITDA falls into.
Tourmaline Bio EV-to-EBITDA Calculation
Tourmaline Bio's EV-to-EBITDA for today is calculated as:
Tourmaline Bio's current Enterprise Value is $169.34 Mil.
Tourmaline Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tourmaline Bio (NAS:TRML) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tourmaline Bio's PE Ratio for today is calculated as:
Tourmaline Bio's share price for today is $14.50.
Tourmaline Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Tourmaline Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Tourmaline Bio (Tourmaline Bio) Business Description
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRML has been successfully added to your